Events Partner Content 2nd Integrin-Targeted Drug Development Summit In collaboration with leading integrin drug developers, including Genentech, 7 Hills Pharm
News Rare diseases have tenfold higher impact on healthcare costs... A new study has suggested that the economic burden posed by rare diseases is around 10 times higher than for common "mass market" conditions.
R&D Rare Disease R&D: one step forward, but a long road ahead With over 40% of all medicines in the pipeline aimed at rare diseases, the future looks positive for increasing the number of treatments available.
News Orphazyme 'looking at options' after lead drug hits buffers ... Orphazyme's hopes of getting EU approval for its Niemann-Pick disease type C (NPC) therapy arimoclomol after a rejection by the US FDA last year are dwindling fast.
Events Partner Content Real-World Evidence 2022: Rare Diseases and Innovative Thera... RWE Live convenes those involved in RWE, HTA and more.
Events Partner Content 2nd Mitochondria-Targeted Drug Development Summit Therapies for mitochondrial dysfunction
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
